Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study

L. B. Seeff; E. C. Wright; H. J. Zimmerman; H. J. Alter; A. A. Dietz; B. F. Felsher; J. D. Finkelstein; P. Garcia-Pont; J. L. Gerin; H. B. Greenlee; J. Hamilton; P. V. Holland; P. M. Kaplan; T. Kiernan; R. S. Koff; C. M. Leevy; V. J. McAuliffe; N. Nath; R. H. Purcell; E. R. Schiff; C. C. Schwartz; C. H. Tamburro; Z. Vlahcevic; R. Zemel; D. S. Zimmon

doi:10.7326/0003-4819-88-3-285

Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study

L. B. Seeff
, E. C. Wright
, H. J. Zimmerman
, H. J. Alter
, A. A. Dietz
, B. F. Felsher
, J. D. Finkelstein
, P. Garcia-Pont
, J. L. Gerin
, H. B. Greenlee
, J. Hamilton
, P. V. Holland
, P. M. Kaplan
, T. Kiernan
, R. S. Koff
, C. M. Leevy
, V. J. McAuliffe
, N. Nath
, R. H. Purcell
, E. R. Schiff

C. C. Schwartz, C. H. Tamburro, Z. Vlahcevic, R. Zemel, D. S. Zimmon

Research output: Contribution to journal › Article › peer-review

282 Scopus citations

Abstract

Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4% of HBIG in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.

Original language	English (US)
Pages (from-to)	285-293
Number of pages	9
Journal	Unknown Journal
Volume	88
Issue number	3
DOIs	https://doi.org/10.7326/0003-4819-88-3-285
State	Published - 1978
Externally published	Yes

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7326/0003-4819-88-3-285

Cite this

Seeff, L. B., Wright, E. C., Zimmerman, H. J., Alter, H. J., Dietz, A. A., Felsher, B. F., Finkelstein, J. D., Garcia-Pont, P., Gerin, J. L., Greenlee, H. B., Hamilton, J., Holland, P. V., Kaplan, P. M., Kiernan, T., Koff, R. S., Leevy, C. M., McAuliffe, V. J., Nath, N., Purcell, R. H., ... Zimmon, D. S. (1978). Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study. Unknown Journal, 88(3), 285-293. https://doi.org/10.7326/0003-4819-88-3-285

Seeff, LB, Wright, EC, Zimmerman, HJ, Alter, HJ, Dietz, AA, Felsher, BF, Finkelstein, JD, Garcia-Pont, P, Gerin, JL, Greenlee, HB, Hamilton, J, Holland, PV, Kaplan, PM, Kiernan, T, Koff, RS, Leevy, CM, McAuliffe, VJ, Nath, N, Purcell, RH, Schiff, ER, Schwartz, CC, Tamburro, CH, Vlahcevic, Z, Zemel, R & Zimmon, DS 1978, 'Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study', Unknown Journal, vol. 88, no. 3, pp. 285-293. https://doi.org/10.7326/0003-4819-88-3-285

@article{6d5972cbce634e99a79fc9fbc23515ac,

title = "Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study",

abstract = "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4\% of HBIG in 5.9\% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6\% and 20.7\% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0\% of ISG and in 3.2\% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.",

author = "Seeff, \{L. B.\} and Wright, \{E. C.\} and Zimmerman, \{H. J.\} and Alter, \{H. J.\} and Dietz, \{A. A.\} and Felsher, \{B. F.\} and Finkelstein, \{J. D.\} and P. Garcia-Pont and Gerin, \{J. L.\} and Greenlee, \{H. B.\} and J. Hamilton and Holland, \{P. V.\} and Kaplan, \{P. M.\} and T. Kiernan and Koff, \{R. S.\} and Leevy, \{C. M.\} and McAuliffe, \{V. J.\} and N. Nath and Purcell, \{R. H.\} and Schiff, \{E. R.\} and Schwartz, \{C. C.\} and Tamburro, \{C. H.\} and Z. Vlahcevic and R. Zemel and Zimmon, \{D. S.\}",

year = "1978",

doi = "10.7326/0003-4819-88-3-285",

language = "English (US)",

volume = "88",

pages = "285--293",

journal = "Unknown Journal",

issn = "0003-1348",

publisher = "JAI Press",

number = "3",

}

TY - JOUR

T1 - Type B hepatitis after needle-stick exposure

T2 - prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study

AU - Seeff, L. B.

AU - Wright, E. C.

AU - Zimmerman, H. J.

AU - Alter, H. J.

AU - Dietz, A. A.

AU - Felsher, B. F.

AU - Finkelstein, J. D.

AU - Garcia-Pont, P.

AU - Gerin, J. L.

AU - Greenlee, H. B.

AU - Hamilton, J.

AU - Holland, P. V.

AU - Kaplan, P. M.

AU - Kiernan, T.

AU - Koff, R. S.

AU - Leevy, C. M.

AU - McAuliffe, V. J.

AU - Nath, N.

AU - Purcell, R. H.

AU - Schiff, E. R.

AU - Schwartz, C. C.

AU - Tamburro, C. H.

AU - Vlahcevic, Z.

AU - Zemel, R.

AU - Zimmon, D. S.

PY - 1978

Y1 - 1978

N2 - Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4% of HBIG in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.

AB - Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4% of HBIG in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.

UR - https://www.scopus.com/pages/publications/0017878739

UR - https://www.scopus.com/pages/publications/0017878739#tab=citedBy

U2 - 10.7326/0003-4819-88-3-285

DO - 10.7326/0003-4819-88-3-285

M3 - Article

C2 - 343678

AN - SCOPUS:0017878739

SN - 0003-1348

VL - 88

SP - 285

EP - 293

JO - Unknown Journal

JF - Unknown Journal

IS - 3

ER -

Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this